Phase I study of vemurafenib in children with recurrent or progressive BRAF(V600E) mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002)

Background: BRAF(V600E) mutation is present in a subset of pediatric brain tumors. Vemurafenib is an oral, selective ATP-competitive inhibitor of BRAF(V600E) kinase. The goal of this multi-center study conducted through the Pacific Pediatric Neuro-Oncology Consortium (PNOC) was to determine the reco...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicolaides, Theodore, Nazemi, Kellie J., Crawford, John, Kilburn, Lindsay, Minturn, Jane, Gajjar, Amar, Gauvain, Karen, Leary, Sarah, Dhall, Girish, Aboian, Mariam, Robinson, Giles, Long-Boyle, Janel, Wang, Hechuan, Molinaro, Annette M., Mueller, Sabine, Prados, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260122/
https://www.ncbi.nlm.nih.gov/pubmed/32523649
http://dx.doi.org/10.18632/oncotarget.27600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260122/
https://www.ncbi.nlm.nih.gov/pubmed/32523649
http://dx.doi.org/10.18632/oncotarget.27600

Ejemplares similares